Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin pharmacodynamic breakpoints in critically ill patients on CVVHD
NL-OMON41806Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ciprofloxacin in bacterial disease, sponsored by Leiden University Medical Center. Primary endpoint: Theoretical pharmacodynamic breakpoint for efficacy. Started Feb 2015; status: active, not recruiting.
02
Drugs
ciprofloxacin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON41806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41806.